A multivariate analysis of the survival of patients with aggressive lymphoma: Variations in the predictive value of prognostic factors during the course of the disease

Cancer

Volumn 82, Issue 10, 1998, Pages 1952-1962

  Mounier, Nicolas ^a   Morel, Pierre ^b   Haioun, Corinne ^a   Coiffier, Bertrand ^c   Tilly, Herve ^d   Chatelain, Christian ^e   Lederlin, Pierre ^f   Thyss, Antoine ^g   Herbrecht, Raoul ^h   Gisselbrecht, Christian ⁱ   Lepage, Eric ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b Centre Hospitalier de LENS   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^f CHU NANCY BRABOIS   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h HÔPITAL DE HAUTEPIERRE   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

Hazard function; Multivariate analysis; Non Hodgkin's lymphoma; Prognostic factors; Survival

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; VINDESINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; FEMALE; FOLLOW UP; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 0032525213     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980515)82:10<1952::AID-CNCR20>3.0.CO;2-R     Document Type: Article

References (31)

1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
2. Rosenberg SA. Validity of the Ann Arbor staging classification for non-Hodgkin's lymphoma. Cancer Treat Rep 1977;61:1023-7.
3. Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, et al. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986;104:757-65.
4. Jagannath S, Velasquez WS, Tucker SL, Fuller LM, Mc Laughlin PW, Mannig JT, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986;4:859-65.
5. Danieu L, Wong G, Koziner B, Clarkson B. Predictive model for prognostic model in advanced diffuse histiocytic lymphoma. Cancer Res 1986;46:5372-9.
6. Coiffier B, Lepage E. Prognosis of aggressive lymphoma: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989;74:558-64.
7. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphoma: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991;9:211-9.
8. The international non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive lymphoma. N Engl J Med 1993;329:987-94.
9. Cox DR. Regression model and life tables. J R Stat Soc B 1972;34:187-220.
10. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N, et al. LNH-84 regimen a multicentric study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989;7:1018-26.
11. Tilly H, Coiffier B, Brice P. Localized low-bulk aggressive Ivmphomas treated with chemotherapy alone in the LNH-87 protocol: a GKLA study [Abstract P111]. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993:98.
12. Bosly A, Lepage E, Coiffier B, Dupriez B, Herbrecht R, Fillet G, et al. Alternating does not improve results in poor prognosis aggressive lymphoma. LNH-87 protocol group 3: a GELA study [Abstract 530]. Thirty-fifth meeting of the American Society of Hematology, St. Louis, Missouri, 1993;82:136a.
13. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly A, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission. J Clin Oncol 1994;12:2543-51.
14. Coiffier B. Fourteen years of high-dose CHOP (ACVBP regimen): preliminary conclusions about the treatment of aggressive lymphoma patients. Ann Oncol 1995;6:211-7.
15. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Prentice RL, Kalbfleisch JD. Hazard rate model with covariates. Biometrics 1979;35:25-39.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
18. Anderson JA, Senthilselvan A. A two step regression model for hazard functions. Appl Stat 1982;31:44-51.
19. Gore SM, Pocock SJ, Keer GR. Regression model and non-proportional hazards in the analysis of breast cancer survival. Appl Stat 1984;33:176-95.
20. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has high-risk disease. Blood 1994;83:1165-73.
21. Harrel FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
22. Grambsch P, Therneau T. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika 1994; 81:515-26.
23. Patte C, Michon J, Frappaz D, Leverger G, Rubie H, Soussain C, et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 1994;7:339-48.
24. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, et al. Lymphoma classification: the gap between biology and clinical management is closing. Blood 1996; 88:4085-9.
25. Gisselbrecht C, Gaulard Ph, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphoma [Abstract 1159]. Thirty-eighth meeting of the American Society of Hematology, Orlando, Florida, 1996;88:293a.
26. Coiffier B, Anderson I, Armitage J, Berger F, Cavalli F, Chan W, et al. Clinical prognostic factors are stronger predictors of outcome in non-Hodgkin's lymphoma than pathologic subtype [Abstract 1160]. Thirty-eighth meeting of the American Society of Hematology, Orlando, Florida, 1996;88:293a.
27. Hermine O, Haioun C, Lepage E, D'Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87:265-72.
28. Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, Mclaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate deshydrogenase levels. J Clin Oncol 1989;7:1518-24.
29. Roggero E, Zucca E, Bertoni F, Bernier J, Cavalli F. Comparison of prognostic models for diffuse large B cell lymphoma: can β2-microglobulin improve upon the International Prognostic Index? [Abstract 70] Thirty-third meeting of the American Society of Clinical Oncology, Denver, 1997;16:20a.
30. Philip T, Guglielmi C, Hagenbeek A, Somer R, Van Der Lelie H, Bron D, et al. Autologous bone-marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
31. Philip T, Gomez F, Bosly A, Biron P, Blay JY, Coiffier B, et al. Salvage treatment for chemotherapy resistant diffuse non-Hodgkin's lymphoma: review of the 215 patients of the PARMA study and rationale for a second prospective study [Abstract 1278]. Thirty-second meeting of the American Society of Clinical Oncology, Seattle, 1996; 15:417a.